RXDX News and Press, Prometheus Biosciences Inc. From 12/07/21

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in c...

Prometheus Biosciences (NASDAQ:RXDX): Q3 GAAP EPS of -$0.70 misses by $0.12. Revenue of $1.01M (+180.6% Y/Y) beats by $0.68M. Press Release For further details see: Prometheus Biosciences EPS misses by $0.12, beats on revenue

- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in ulcerative colitis and Phase 2a in Crohn’s disease with topline data from both trials...

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the trea...

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Th...

Prometheus has built the leading platform and data set for IBD drug development that has enabled partnerships, a diverse pipeline, and non-dilutive capital. IBD is a market opportunity representing millions of patients, which has had little innovation over the last 2 decades. The ...

You can read full article here. Drop here! For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 ...

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021. “As I reflect on my time with Tachi, one w...

- First Anti-TL1A trial in Crohn’s Disease - - APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- SAN DIEGO, Aug...